Leerink and TD Cowen acted as joint book running managers for the offering.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGEN:
- NervGen Pharma secondary being re-offered at $2.50 per share
- NervGen Pharma announces common share offering, no amount given
- NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows
- NervGen Pharma reports Q1 EPS (2c), consensus (7c)
- NervGen Pharma Narrows Quarterly Loss but Cash Reserves Decline in Q1 2026 Filing